Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Genzyme completes Impath buy:

This article was originally published in Clinica

Executive Summary

Genzyme has completed its $215m cash acquisition of Impath's oncology testing service business, which will become part of its Genzyme Genetics business. The deal brings Genzyme laboratories in New York, Phoenix, Arizona, and Los Angeles, as well as a clinical trial testing facility serving companies developing new drugs. The purchase goes hand in hand with that of cancer drug developer Ilex Oncology in creating a strong oncology offering in both therapeutics and diagnostics at Genzyme. Impath's technology includes molecular diagnostics, flow cytometry, cytogenetics and immunohistochemistry.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts